We're celebrating the year of '23! We help people access, understand and benefit from the human genome.
23andMe Claimed Company
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the companyās mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the worldās largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. read more
HR or Marketing? Claim Your Free Employer Account
Jennifer Low ā Head of Therapeutics Development at 23andMe
Executive Bio
Jennifer Low joined 23andMe in 2018 as Head of Therapeutics Development. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies.
Jennifer has considerable drug development experience and has most recently worked as a consultant and advisor to biotech CEOs and investors on their drug development strategies. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that, she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), and Cotellic (mek) clinical development programs among many others.
Jennifer has considerable drug development experience and has most recently worked as a consultant and advisor to biotech CEOs and investors on their drug development strategies. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that, she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), and Cotellic (mek) clinical development programs among many others.
Executive Team Culture Ratings from 23andMe Employees
TOP
50%
23andMe's Executive Team scores in the Top 50%
of similar sized companies on Comparably
of similar sized companies on Comparably
23andMe's Executive Team at a Glance
Based on 26 ratings, 23andMe's employees are less satisfied with their Executive Team and give them a āC+ā or 65/100. On average, Men provided higher ratings for their Executive Team compared to Women.
23andMe's Executive Team ranks in the Bottom 40% of other companies in San Francisco and Top 50% of other companies on Comparably that also have 501-1,000 Employees.
×